US2418033A - Diagnostic compositions - Google Patents

Diagnostic compositions Download PDF

Info

Publication number
US2418033A
US2418033A US701403A US70140346A US2418033A US 2418033 A US2418033 A US 2418033A US 701403 A US701403 A US 701403A US 70140346 A US70140346 A US 70140346A US 2418033 A US2418033 A US 2418033A
Authority
US
United States
Prior art keywords
solid
mixture
urine
grams
cupric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US701403A
Inventor
Kamlet Jonas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Laboratories Inc filed Critical Miles Laboratories Inc
Priority to US701403A priority Critical patent/US2418033A/en
Application granted granted Critical
Publication of US2418033A publication Critical patent/US2418033A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]
    • Y10T436/144444Glucose

Definitions

  • the present invention relates to diagnostic compositions and, more particularly, to diagnostic compositions suitable for the qualitative detection and quantative estimation of reducing carbohydrates (e. g., glucose, levulose, arabinose) in body fluids (e. g., urine, cerebrospinal fluid, milk). It has for its object to provide a simple, rapid and convenient method for performing these tests with a high degree of accuracy and without the necessity of employing an extraneous source of heat, such as a gas burner, alcohol lamp or ignited hexamethylenetetramine tablet.
  • reducing carbohydrates e. g., glucose, levulose, arabinose
  • body fluids e. g., urine, cerebrospinal fluid, milk.
  • the qualitative and quantative estimations of glucose in urine are at present the best means available to the physician for controlling his diabetic patients.
  • the daily dosage of insulin is usually determined by the presence or absence of glucose in the fasting urine, and, in the majority of diabetic patients, such a determination must be performed at least once daily. This is usually done by the patient himself.
  • cupric ions to the cuprous form by glucose
  • a member of the group of solid acids and acid reacting salts forming water-soluble complexes with cupric ions in'alkaline solution which group consists of citric acid, tartaric acid, the alkali metal acid salts of citric and tartaric acids, the alkali metal and alkaline-earth metal hemibasic and monobasio salt of orthophosphoric acid, and the alkali metal and alkaline-earth usually 3 mixtures are tableted so that each tablet Will be sufficient to make one diagnostic determination.
  • these compositions either in powder or tablet form, are mixed with a small amount of an aqueous specimen such as urine, they dis" solve rapidly with the evolution of a considerable amount of heat. It, may be desirable to dilute the urine specimen with water.
  • the color of the suspension may be compared with the panels of a standard color chart of known concentrations of glucose (or other reducing carbohydrates) in urine (or any other specimen being tested).
  • the intensity of the observed color of the precipitate is directly proportional to the concentration of the colored substance (i. e., cuprous oxide).
  • the concentration of the cuprous oxide is also directly proportional to the concentration of reducing carbohoydrates originally present in thespecimen, the observed color is likewise directly proportional to the concentration of the reducing substance.
  • diluents, excipients, and ancillary or auxiliary agents may be incorporated into the dry diagnostic compositions.
  • a minor proportion of an alkali metal bicarbonate e. 3., sodium bicarbonate
  • the dry diagnostic composition containing such a bicarbonate is added to the liquid specimen being tested, the solid acid or acid reacting salt therein will interact with the alkali metal bicarbonate liberating gaseous carbon dioxide.
  • the effervescence thus produced serves to accelerate the mechanical disintegration of the composition, especially if it is in tablet form. The reaction is thus speeded up, and the determination is effected more promptly. Since the total heat evolution is thereby elIected within a shorter period, there is less loss of heat by radiation, conduction and vaporization, and traces of reducing carbohydrates are detectable, which might otherwise go undetected.
  • a desiccating agent such as calcium chloride, and diluents and excipients, such as kaolin and talc, may be employed without adversely afiecting the sensitivity and specificity of thediagnostic compositions.
  • diluents and excipients such as kaolin and talc
  • auxiliary agents such as creatinine and the hydrophilic colloids, may be incorporated, their presence in the test solution being advised by Sheftel, to prevent the formation of the red form of cuprous oxide.
  • Typical examples of ingredients from group (a) above that may be used (1. e., water soluble cupric salts) in preparing the diagnostic compositions are cupric sulphate, cupric chloride, and cupric acetate.
  • Typical examples of members of group (b) i. e., oxides and hydroxide-s of alkaline metals
  • members of group (b) i. e., oxides and hydroxide-s of alkaline metals
  • sodium hydroxide and potassium hydroxide are sodium hydroxide and potassium hydroxide.
  • lithium oxide and hydroxide are more expensive than the other members of this group, their use in some compositions may be justified by reason of their comparatively low hygroscopie city.
  • Sodium and potassium hydroxides are the preferred hydroxides since their heats of solution are more than double that of lithium hydroxide.
  • sodium and potassium oxides both have considerably higher heats of solution than lithium oxide.
  • Typical examples oi ingredients of group (0) i. e., solid acids and acid reacting salts which form water soluble complexes with cupric ions in alkaline solution
  • group (0) i. e., solid acids and acid reacting salts which form water soluble complexes with cupric ions in alkaline solution
  • citric acid monohydrate
  • tartaric acid hemibasic sodium orthophosphate (NaH2PO4l-I3PO4).
  • compositions covered by this invention are intended to define and illustrate, but in no Way to limit the invention to the particular re-agents or proportions describedtherein.
  • These compositions may be used in the form of powder, or dispensed in pellets, or they may be pressed into unitary reaction tablets of such a size as is convenient for the performance of a single test.
  • Example I One kilogram of finely powdered caustic soda is thoroughly mixed with 500 grams of citric acid (monohydrate) and 50 grams of anhydrous cupric sulfate, until the mixture is homogeneous. It is then pressed into five grain tablets.
  • a tablet is placed into a testtube and 0.5 cc. of urine is added dropwise. A vigorous reaction occurs and the tablet dissolves in the urine with the evolution of considerable heat. In the presence of 0.075% or more of glufor reducing carbohydrates.
  • Example II Two kilograms of sixty mesh powdered caustic soda are thoroughly mixed with 200 grams of powdered anhydrous monobasic sodium orthophosphate and 20 grams of anhydrous cupric sulfate, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets.
  • a tablet is dropped into a round bottomed test tube containing five drops of the urine and 10 drops of water. A. vigorous reaction occurs and the tablet dissolves in the urine with the evolution of considerable heat. In the presence of 0.050% or more of glucose in the urine a suspension of cuprous oxide will be observed in the tube. The color of this suspension may be compared with that of the panels of a standard color chart to obtain an estimation of the amount of glucose present.
  • compositions are quite specific for reducing carbohydrates. Chloroform, uric acid, creatinine and'albumin do not interfere with this test, as they do in the case of the Fehling test and the Nylander reaction.
  • Example III Two kilograms of sixty mesh powdered caustic soda are thoroughly mixed with 1'76 grams of powdered hemibasic sodium orthophosphate and grams of anhydrous cupric sulfate, until the mixtur is homogeneous. It is then compressed into five grain unitary reaction tablets.
  • Example II These tablets are used in the manner described in Example II.
  • the sensitivity and specificity are equally as good as those described in Example IL
  • Example IV Two kilograms of sixty mesh powdered caustic soda are thoroughly mixed with 180 grams of powdered dibasic sodium pyrophosphate (sodium acid pyrophosphate), 20 grams of powdered sodium bicarbonate and 20 grams of anhydrous cupric sulfate, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets, which are effervescent in use.
  • dibasic sodium pyrophosphate sodium acid pyrophosphate
  • sodium bicarbonate sodium bicarbonate
  • cupric sulfate anhydrous cupric sulfate
  • Example 1 These tablets are used in the manner described in Example I.
  • the sensitivity and specificity are equally as good as those described in Example 1.
  • Example V Two kilograms of sixty mesh powdered caustic soda are thoroughly mixed with 200 grams of powdered anhydrous hemibasic calcium orthophosphate, 30 grams of sodium bicarbonate and grams of anhydrous cupric sulfate, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets, which are effervescent.
  • Example VI Two kilograms of caustic potash chips are thoroughly mixed with 180 grams of monobasic calcium orthophosphat monohydrate crystals and 20 grams of anhydrous cupric chloride, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets.
  • Example VII Two kilograms of anhydrous powdered lithium hydroxide are mixed with 250 grams of powdered monobasic potassium orthophosphate, 25 grams of sodium bicarbonate, 25 grams of anhydrous cupric sulfate and 50 grams of powdered talc, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets.
  • Example VIII Two kilograms of powdered dibasic sodium acid pyrophosphate are thoroughly mixed with I00 grams of powdered sodium oxide (NazO), 20 grams of powdered sodium bicarbonate and 20 grams of anhydrous cupric sulfate, under the scrupulous exclusion of moisture, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets.
  • powdered sodium oxide NazO
  • powdered sodium bicarbonate 20 grams
  • anhydrous cupric sulfate anhydrous cupric sulfate
  • the above composition Upon dissolution in water, the above composition is alkaline, and generates sufiicient heat for the formation of cuprous oxide.
  • compositions within the scope of this invention it is desirable, although by no means imperative, to use anhydrous reagents instead of the corresponding hydrates.
  • anhydrous cupric sulfate yields more stable compositions than the hydrate salt.
  • Anhydrous monobasic sodium orthophosphate is preferable to the hydrate, and this preference holds for all of the ingredients having two forms of high and low (or no) water content.
  • the heat evolved during the reaction of the diagnostic compositions of this invention wit-h urine, or similar specimens, is predominantly due to twoexothermic reactions.
  • One of these is the heat of solution of the alkali metal oxide, or hydroxide, in the aqueous fluid.
  • the other is the heat of neutralization of the solid acid or acid reacting salt with the alkali metal hydroxide in solution.
  • the heat evolved will more than suffice to efiect the reduction of the cupric complex to cuprous oxide, which forms a precipitate of characteristic color.
  • the dry diagnostic compositions may beused for the qualitative detection and quantitative estimation of reducing carbohydrates other than glucose. Thus, they may be used to detect pentosuria, to estimate the amount of galactose in urine during a galactose tolerance test for depatic function or hyperthyroidism, or the amount of lactose in'milk.
  • a diagnostic composition in solid dry form comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material supplied by the mixture said ingredients comprising essentially: a minor quantity of a water soluble solid cupric salt; a solid acidic material selected from the group consisting of citric acid, tartaric acid, an alkali metal acid salt of citric acid, an alkali metal acid salt of tartaric acid, an alkali metal monobasic orthophosphate, an alkali metal dibasic pyrcphosphate, an alkali metal hemibasic orthophosphate, an alkaline-earth metal monobasic o-rthophosphate, an alkaline-earth metal dibasic pyrophosphate, and an alkaline-earth metal hemi-basic orthophosphate; and a quantity of solid alkali material selected from the group consisting of alkali metal oxides and alkali meta] hydroxides, the said alkali metal oxide
  • a diagnostic composition in solid dry form comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material sup-plied by the mixture, said ingredients comprising essentially a minor quantity of a water soluble solid cupric salt, a quantity of solid citric acid, and a quantity of solid alkali material selected from the group consisting of alkali metal oxides and alkali metal hydroxides, the said alkali material being present in excess of that required to neutralize the solid citric acid in the mixtur and in an amount adequate to generate sufiicient heat to form said cuprous oxide.
  • a diagnostic composition in solid dry form comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide, by action of the sugar on a material supplied by the mixture, said ingredients comprising essentially a minor quantity of a water soluble solid cupric salt, a quantity of solid tartaric acid, and a quantity of solid alkali material selected from the group consisting of alkali metal oxides and alkali metal hydroxides, the said alkali material being present in excess of that required to newtralize the solid tartaric acid in the mixture and in an amount adequate to generate sufficient heat to form said cuprous oxide.
  • a diagnostic composition in solid dry form comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material supplied by the mixture, said ingredients comprising essentially a minor quantity of a Water soluble solid cupric salt, a quantity of solid hemibasic sodium orthophosphate, and a quantity of solid alkali material selected from the group consisting of alkali metal oxides and alkali metal hydroxides, the said alkali material being present in excess of that required to neutralize the hemibasic sodium orthophosphate in the mixture, and in an amount adequate to generate sumcient heat to 8 acid in the mixture and in an amount adequate to generate suiiicient heat to form said cuprous oxide.
  • A'dia nostic composition in solid dry form comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material supplied. by the mixture, said ingredients comprising essentially a minor quantity of solid cupric sulfate, a quantity of solid tartaric acid, and. a quantity of solid sodium hydroxide, the latter being present in excess of that required to neutralize the tartaric acid in the, mixture, and in an amount adequate to generate, sufficient heat to form said cuprous oxide.
  • a diagnostic composition in solid dry form comprising a, mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material supplied by the mixture, said ingredients comprising essentially, a minor quantity of solid cupric sulfate, a quantity of solid hemibasic sodium orthophosphate, and a quantity of solid sodium hydroxide,

Description

iatenteci Mar. 25, 1947 DIAGNOSTIC COMPOSITIONS Jonas Kamlet, New York, N. Y., assignor to Miles Laboratories, Inc., Elkhart, Ind., a corporation of Indiana No Drawing. Application October 5, 1946, Serial No. 701,403
The present invention relates to diagnostic compositions and, more particularly, to diagnostic compositions suitable for the qualitative detection and quantative estimation of reducing carbohydrates (e. g., glucose, levulose, arabinose) in body fluids (e. g., urine, cerebrospinal fluid, milk). It has for its object to provide a simple, rapid and convenient method for performing these tests with a high degree of accuracy and without the necessity of employing an extraneous source of heat, such as a gas burner, alcohol lamp or ignited hexamethylenetetramine tablet.
The present application is a continuation-inpart of my copending applications, Serial No. 343,777 filed July 3, 1940, and Serial No. 500,558, filed August 30, 1943.
The qualitative and quantative estimations of glucose in urine are at present the best means available to the physician for controlling his diabetic patients. The daily dosage of insulin is usually determined by the presence or absence of glucose in the fasting urine, and, in the majority of diabetic patients, such a determination must be performed at least once daily. This is usually done by the patient himself.
Methods heretofore available were based on the principle of heating a mixture of measured aliquots of urine and an alkaline copper solution (such as Benedicts, Fehlings, Folin-McEllroy) or an alkaline bismuth solution (such as Nylander, Almen). In qualitative estimations, the precipitation of cuprous oxide from the cuprio compound, in the former case, or the reduction of the bismuth ion to black metallic bismuth, in the latter case, would indicate the presence of a reducing carbohydrate. In quantitative estimations, the usual method employed heretofore has been that of Benedict (Journal of the American Medical Association, vol. 57, page 1193, 1911). This involves adding measured amounts of urine to an aliquot of a standard solution, while boiling the latter, until the blue cupric compound contained therein is completely decolorized, forming cuprous thiocyanate. By a calculation, the percentage of reducing substance in the urine is determined.
Sheftel, United States patent, No. 1,769,862, has described a method for the quantative determination of sugar in urine based on the following steps: (a) Measured aliquots of a special modifled Benedict solution containing creatinine and a hydrophile colloid are mixed with a measured aliquot of urine; (b) the mixture is heated in boiling water for five minutes; if a change in the original blue color appears, the solution 7 Claims. (Cl. 252-408) is compared with a color scale and the corresponding percentage of sugar is estimated.
All of the procedures thus mentioned have one great drawback. They all require an extraneous source of heat. It is obvious that a diabetic going about his daily business, or a military physician in the field, or a physician at his patients bedside, cannot always have a gas burner available. Attempts to heat water by igniting hexamethylenetetramine tablets are futile.
Since the reduction of cupric ions to the cuprous form by glucose is effected only at advanced temperatures, it is th further purpose of this invention to provide dry, solid, alkaline, cupric ioncontaining, compositions which will dissolve in urine with a strongly exothermic reaction, and which will be reduced to cuprous oxide if glucose or any other reducing carbohydrate is present in the urine. This will be effected without recourse to any extraneous source of heat.
The basis of all diagnostic solutions containing alkaline cupric ions heretofore employed is: (a) a cupric salt, such ascupric sulfate; (b) an alkaline-reacting substance, such as sodium carbonate, or potassium hydroxide; (c) a member of the group of normal salts that are capable of holding cupric hydroxide in solution. Fehling (Annalen, vol. 72, page 106, of 1849) used normal alkali-metal tartrates (Rochelle salts), while Benedict (J. Biol. Chem. vol. 3, page 101, of 1907) used normal alkali-metal citrates and Folin- McEllroy (J. Biol. Chem, vol. 33, page 513, of 1918) used normal alkali-metal phosphates, pyrophosphates and thiocyanates.
I have found that stable diagnostic compositions of excellent specificity for reducing carbo hydrates, and fulfilling the objects of the present invention, may be obtained by preparing solid, dry mixtures of the following ingredients in proper proportions:
(a) A water soluble cupric salt.
(b) A solid alkali material of the group consisting of the oxides and hydroxides of the alkali metals, and
(c) A member of the group of solid acids and acid reacting salts forming water-soluble complexes with cupric ions in'alkaline solution, which group consists of citric acid, tartaric acid, the alkali metal acid salts of citric and tartaric acids, the alkali metal and alkaline-earth metal hemibasic and monobasio salt of orthophosphoric acid, and the alkali metal and alkaline-earth usually 3 mixtures are tableted so that each tablet Will be sufficient to make one diagnostic determination. When these compositions, either in powder or tablet form, are mixed with a small amount of an aqueous specimen such as urine, they dis" solve rapidly with the evolution of a considerable amount of heat. It, may be desirable to dilute the urine specimen with water. In the absence of a reducing carbohydrate, a clear blue solution is obtained. In the presence of a reducing sugar, a green, yellow or brownish red precipitate of cuprous oxide is obtained, which is held in suspension by the highly concentrated alkaline sol'ution. To determine quantitatively the amount of reducing carbohydrate present in the urine specimen, the color of the suspension may be compared with the panels of a standard color chart of known concentrations of glucose (or other reducing carbohydrates) in urine (or any other specimen being tested).
In accordance with Beers law, on which the entire art of colorimetry is based, the intensity of the observed color of the precipitate is directly proportional to the concentration of the colored substance (i. e., cuprous oxide). However, since the concentration of the cuprous oxide is also directly proportional to the concentration of reducing carbohoydrates originally present in thespecimen, the observed color is likewise directly proportional to the concentration of the reducing substance.
If desired, diluents, excipients, and ancillary or auxiliary agents may be incorporated into the dry diagnostic compositions. Thus, a minor proportion of an alkali metal bicarbonate (e. 3., sodium bicarbonate) may be added. When the dry diagnostic composition containing such a bicarbonate is added to the liquid specimen being tested, the solid acid or acid reacting salt therein will interact with the alkali metal bicarbonate liberating gaseous carbon dioxide. The effervescence thus produced serves to accelerate the mechanical disintegration of the composition, especially if it is in tablet form. The reaction is thus speeded up, and the determination is effected more promptly. Since the total heat evolution is thereby elIected within a shorter period, there is less loss of heat by radiation, conduction and vaporization, and traces of reducing carbohydrates are detectable, which might otherwise go undetected.
A desiccating agent, such as calcium chloride, and diluents and excipients, such as kaolin and talc, may be employed without adversely afiecting the sensitivity and specificity of thediagnostic compositions. Auxiliary agents, such as creatinine and the hydrophilic colloids, may be incorporated, their presence in the test solution being advised by Sheftel, to prevent the formation of the red form of cuprous oxide.
Typical examples of ingredients from group (a) above that may be used (1. e., water soluble cupric salts) in preparing the diagnostic compositions are cupric sulphate, cupric chloride, and cupric acetate.
Typical examples of members of group (b) (i. e., oxides and hydroxide-s of alkaline metals) that may be used in the diagnostic compositions are sodium hydroxide and potassium hydroxide. Although lithium oxide and hydroxide are more expensive than the other members of this group, their use in some compositions may be justified by reason of their comparatively low hygroscopie city. Sodium and potassium hydroxides are the preferred hydroxides since their heats of solution are more than double that of lithium hydroxide. Likewise, sodium and potassium oxides both have considerably higher heats of solution than lithium oxide.
Typical examples oi ingredients of group (0) (i. e., solid acids and acid reacting salts which form water soluble complexes with cupric ions in alkaline solution) that may be used in preparing the dry diagnostic compositions are: citric acid (monohydrate), tartaric acid and hemibasic sodium orthophosphate (NaH2PO4l-I3PO4).
The following examples of typical compositions covered by this invention are intended to define and illustrate, but in no Way to limit the invention to the particular re-agents or proportions describedtherein. These compositions may be used in the form of powder, or dispensed in pellets, or they may be pressed into unitary reaction tablets of such a size as is convenient for the performance of a single test.
Example I One kilogram of finely powdered caustic soda is thoroughly mixed with 500 grams of citric acid (monohydrate) and 50 grams of anhydrous cupric sulfate, until the mixture is homogeneous. It is then pressed into five grain tablets.
To perform a test, a tablet is placed into a testtube and 0.5 cc. of urine is added dropwise. A vigorous reaction occurs and the tablet dissolves in the urine with the evolution of considerable heat. In the presence of 0.075% or more of glufor reducing carbohydrates.
Example II Two kilograms of sixty mesh powdered caustic soda are thoroughly mixed with 200 grams of powdered anhydrous monobasic sodium orthophosphate and 20 grams of anhydrous cupric sulfate, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets.
To perform a test on a suspected urine, a tablet is dropped into a round bottomed test tube containing five drops of the urine and 10 drops of water. A. vigorous reaction occurs and the tablet dissolves in the urine with the evolution of considerable heat. In the presence of 0.050% or more of glucose in the urine a suspension of cuprous oxide will be observed in the tube. The color of this suspension may be compared with that of the panels of a standard color chart to obtain an estimation of the amount of glucose present. I
The sensitivity of this composition is about 0.050% of glucose, 0.080% of lactose and 0.080% of arabinose. Similarly, these compositions are quite specific for reducing carbohydrates. Chloroform, uric acid, creatinine and'albumin do not interfere with this test, as they do in the case of the Fehling test and the Nylander reaction.
Example III Two kilograms of sixty mesh powdered caustic soda are thoroughly mixed with 1'76 grams of powdered hemibasic sodium orthophosphate and grams of anhydrous cupric sulfate, until the mixtur is homogeneous. It is then compressed into five grain unitary reaction tablets.
These tablets are used in the manner described in Example II. The sensitivity and specificity are equally as good as those described in Example IL Example IV Two kilograms of sixty mesh powdered caustic soda are thoroughly mixed with 180 grams of powdered dibasic sodium pyrophosphate (sodium acid pyrophosphate), 20 grams of powdered sodium bicarbonate and 20 grams of anhydrous cupric sulfate, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets, which are effervescent in use.
These tablets are used in the manner described in Example I. The sensitivity and specificity are equally as good as those described in Example 1.
Example V Two kilograms of sixty mesh powdered caustic soda are thoroughly mixed with 200 grams of powdered anhydrous hemibasic calcium orthophosphate, 30 grams of sodium bicarbonate and grams of anhydrous cupric sulfate, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets, which are effervescent.
Example VI Two kilograms of caustic potash chips are thoroughly mixed with 180 grams of monobasic calcium orthophosphat monohydrate crystals and 20 grams of anhydrous cupric chloride, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets.
Example VII Two kilograms of anhydrous powdered lithium hydroxide are mixed with 250 grams of powdered monobasic potassium orthophosphate, 25 grams of sodium bicarbonate, 25 grams of anhydrous cupric sulfate and 50 grams of powdered talc, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets.
Example VIII Two kilograms of powdered dibasic sodium acid pyrophosphate are thoroughly mixed with I00 grams of powdered sodium oxide (NazO), 20 grams of powdered sodium bicarbonate and 20 grams of anhydrous cupric sulfate, under the scrupulous exclusion of moisture, until the mixture is homogeneous. It is then compressed into five grain unitary reaction tablets.
Upon dissolution in water, the above composition is alkaline, and generates sufiicient heat for the formation of cuprous oxide.
Because of the hygroscopicity of compositions within the scope of this invention, it is desirable, although by no means imperative, to use anhydrous reagents instead of the corresponding hydrates. Thus anhydrous cupric sulfate yields more stable compositions than the hydrate salt. Anhydrous monobasic sodium orthophosphate is preferable to the hydrate, and this preference holds for all of the ingredients having two forms of high and low (or no) water content. However,
if a hydrate does not have a tendency to deli-v quesce as the temperatures encountered in'the 10- forms no hydrate.
The heat evolved during the reaction of the diagnostic compositions of this invention wit-h urine, or similar specimens, is predominantly due to twoexothermic reactions. One of these is the heat of solution of the alkali metal oxide, or hydroxide, in the aqueous fluid. The other is the heat of neutralization of the solid acid or acid reacting salt with the alkali metal hydroxide in solution. The heat evolved will more than suffice to efiect the reduction of the cupric complex to cuprous oxide, which forms a precipitate of characteristic color.
The dry diagnostic compositions may beused for the qualitative detection and quantitative estimation of reducing carbohydrates other than glucose. Thus, they may be used to detect pentosuria, to estimate the amount of galactose in urine during a galactose tolerance test for depatic function or hyperthyroidism, or the amount of lactose in'milk.
Iclaim:
, 1. .A diagnostic composition in solid dry form comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material supplied by the mixture said ingredients comprising essentially: a minor quantity of a water soluble solid cupric salt; a solid acidic material selected from the group consisting of citric acid, tartaric acid, an alkali metal acid salt of citric acid, an alkali metal acid salt of tartaric acid, an alkali metal monobasic orthophosphate, an alkali metal dibasic pyrcphosphate, an alkali metal hemibasic orthophosphate, an alkaline-earth metal monobasic o-rthophosphate, an alkaline-earth metal dibasic pyrophosphate, and an alkaline-earth metal hemi-basic orthophosphate; and a quantity of solid alkali material selected from the group consisting of alkali metal oxides and alkali meta] hydroxides, the said alkali being present in excess of that required to neutralize the solid acidic material in the mixture and in an amount adequate to generate sufficient heat to form said cuprous oxide.
2. A diagnostic composition in solid dry form comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material sup-plied by the mixture, said ingredients comprising essentially a minor quantity of a water soluble solid cupric salt, a quantity of solid citric acid, and a quantity of solid alkali material selected from the group consisting of alkali metal oxides and alkali metal hydroxides, the said alkali material being present in excess of that required to neutralize the solid citric acid in the mixtur and in an amount adequate to generate sufiicient heat to form said cuprous oxide.
3. A diagnostic composition in solid dry form comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide, by action of the sugar on a material supplied by the mixture, said ingredients comprising essentially a minor quantity of a water soluble solid cupric salt, a quantity of solid tartaric acid, and a quantity of solid alkali material selected from the group consisting of alkali metal oxides and alkali metal hydroxides, the said alkali material being present in excess of that required to newtralize the solid tartaric acid in the mixture and in an amount adequate to generate sufficient heat to form said cuprous oxide. I
4. A diagnostic composition in solid dry form comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material supplied by the mixture, said ingredients comprising essentially a minor quantity of a Water soluble solid cupric salt, a quantity of solid hemibasic sodium orthophosphate, and a quantity of solid alkali material selected from the group consisting of alkali metal oxides and alkali metal hydroxides, the said alkali material being present in excess of that required to neutralize the hemibasic sodium orthophosphate in the mixture, and in an amount adequate to generate sumcient heat to 8 acid in the mixture and in an amount adequate to generate suiiicient heat to form said cuprous oxide.
6. A'dia nostic composition in solid dry form comprising a mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material supplied. by the mixture, said ingredients comprising essentially a minor quantity of solid cupric sulfate, a quantity of solid tartaric acid, and. a quantity of solid sodium hydroxide, the latter being present in excess of that required to neutralize the tartaric acid in the, mixture, and in an amount adequate to generate, sufficient heat to form said cuprous oxide.
7. A diagnostic composition in solid dry form comprising a, mixture of ingredients reactive when contacted with an aqueous liquid specimen containing reducing sugar to form cuprous oxide by action of the sugar on a material supplied by the mixture, said ingredients comprising essentially, a minor quantity of solid cupric sulfate, a quantity of solid hemibasic sodium orthophosphate, and a quantity of solid sodium hydroxide,
the latter being present in excess of that required
US701403A 1940-07-03 1946-10-05 Diagnostic compositions Expired - Lifetime US2418033A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US701403A US2418033A (en) 1940-07-03 1946-10-05 Diagnostic compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US615659XA 1940-07-03 1940-07-03
US701403A US2418033A (en) 1940-07-03 1946-10-05 Diagnostic compositions

Publications (1)

Publication Number Publication Date
US2418033A true US2418033A (en) 1947-03-25

Family

ID=26741212

Family Applications (1)

Application Number Title Priority Date Filing Date
US701403A Expired - Lifetime US2418033A (en) 1940-07-03 1946-10-05 Diagnostic compositions

Country Status (1)

Country Link
US (1) US2418033A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2689831A (en) * 1945-02-08 1954-09-21 Us Sec War Detector for lewisite
US2750027A (en) * 1951-08-21 1956-06-12 Cummings Molly Visual indicating devices for producing a color slick or patch at sea or in any waters
US3173880A (en) * 1961-07-13 1965-03-16 William S Pappas Moisture indicator and method of making the same
US3477817A (en) * 1966-04-14 1969-11-11 Ralph J De Falco Diagnostic test for presence of galactose
US3507269A (en) * 1965-04-26 1970-04-21 Homer H Berry Clinical diagnostic device for halitosis
US4325908A (en) * 1980-02-20 1982-04-20 Warner-Lambert Company Theophylline test
US8511323B2 (en) 2009-12-23 2013-08-20 Colgate-Palmolive Company Oral care dispenser and oral care system implementing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2689831A (en) * 1945-02-08 1954-09-21 Us Sec War Detector for lewisite
US2750027A (en) * 1951-08-21 1956-06-12 Cummings Molly Visual indicating devices for producing a color slick or patch at sea or in any waters
US3173880A (en) * 1961-07-13 1965-03-16 William S Pappas Moisture indicator and method of making the same
US3507269A (en) * 1965-04-26 1970-04-21 Homer H Berry Clinical diagnostic device for halitosis
US3477817A (en) * 1966-04-14 1969-11-11 Ralph J De Falco Diagnostic test for presence of galactose
US4325908A (en) * 1980-02-20 1982-04-20 Warner-Lambert Company Theophylline test
US8511323B2 (en) 2009-12-23 2013-08-20 Colgate-Palmolive Company Oral care dispenser and oral care system implementing the same

Similar Documents

Publication Publication Date Title
Fujiwara et al. Determination of thiamine by thiochrome reaction
Sobel et al. A rapid method for the determination of ultramicro quantities of calcium and magnesium.
BROWN et al. The determination of protein-bound iodine by dry ashing
GB575612A (en) Improvements in and relating to analytical compositions in tablet form
US2418033A (en) Diagnostic compositions
Carlson et al. Spectrophotometric determination of silicon
US3447904A (en) Test indicator for the detection of chlorides
Gardner et al. Abnormal membrane sodium transport in Liddle's syndrome
US2283262A (en) Diagnostic composition and method
US3472738A (en) Test implement for detecting peroxidase
US3798000A (en) Agent and method for determination of calcium
USRE23705E (en) Diagnostic compositions
Ingols et al. Urea hydrolysis for precipitating calcium oxalate
Bambach Polarographic determination of arsenic in biological material
McKay Pentose estimation by the orcinol method, with particular reference to plasma pentose
US3310382A (en) Biuret reagent
JPH0677016B2 (en) Improved cancer screening diagnostic miron reagent
US3630958A (en) Test composition and method for detecting reducing sugars in aqueous fluids
US2865718A (en) Urine sugar testing
Thorp A method for the micro-estimation of iron in biological materials
US3425805A (en) Phosphite testing method
US3293146A (en) Composition for detecting guanase and process for diagnosing viral hepatitis therewith
US1543961A (en) Reagent
Körbl et al. The use of fluorescein complexone
US2982700A (en) Diagnostic composition